National Institute on Drug Abuse; Notice of Meeting, 50034 [2020-17817]

Download as PDF 50034 Federal Register / Vol. 85, No. 159 / Monday, August 17, 2020 / Notices indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Advisory Board. Date: September 1, 2020. Open: 1:00 p.m. to 5:45 p.m. Agenda: NCAB Subcommittee Meetings— Subcommittee on Planning and Budget; Ad Hoc Subcommittee on Experimental Therapeutics; Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities; and Ad Hoc Subcommittee on Global Cancer Research. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meetings). Instructions regarding access to the virtual Subcommittee Meetings will be posted at: https://deainfo.nci.nih.gov/advisory/ncab/ ncabmeetings.htm. Name of Committee: National Cancer Advisory Board. Date: September 2, 2020. Open: 1:00 p.m. to 3:15 p.m. Agenda: Director’s and Program reports and presentations; business of the Board. Closed: 3:30 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Contact Person: Paulette S. Gray, Ph.D., Executive Secretary Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W444 Bethesda, MD 20892, 240–276–6340, grayp@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ ncabmeetings.htm, where an agenda, VerDate Sep<11>2014 17:13 Aug 14, 2020 Jkt 250001 instructions for accessing the virtual NCAB meetings, and any additional information for the meetings will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 12, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–17906 Filed 8–14–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Drug Abuse. The meeting will be held as a virtual meeting and is open to the public, as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). A portion of this meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse. Date: September 10, 2020. Closed: 11:00 a.m. to 12:15 p.m. Agenda: To review and evaluate grant applications. Open: 12:45 p.m. to 4:30 p.m. Agenda: Presentations and other business of the Council. Place: National Institutes of Health, National Institute on Drug Abuse, Neurosciences Center Building, 6001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of Extramural Research, Office of the Director, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC 9591, Rockville, MD 20892, 301–443–6487, sweiss@nida.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: www.drugabuse.gov/NACDA/ NACDAHome.html, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: August 11, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–17817 Filed 8–14–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS–CoV–2) and Coronavirus Disease 2019 (COVID–19). Date: August 27, 2020. E:\FR\FM\17AUN1.SGM 17AUN1

Agencies

[Federal Register Volume 85, Number 159 (Monday, August 17, 2020)]
[Notices]
[Page 50034]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17817]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Council on Drug Abuse.
    The meeting will be held as a virtual meeting and is open to the 
public, as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting, should notify the Contact Person listed below in 
advance of the meeting. The open session will be videocast and can be 
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
    A portion of this meeting will be closed to the public in 
accordance with the provisions set forth in sections 552b(c)(4) and 
552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.

    Name of Committee: National Advisory Council on Drug Abuse.
    Date: September 10, 2020.
    Closed: 11:00 a.m. to 12:15 p.m.
    Agenda: To review and evaluate grant applications.
    Open: 12:45 p.m. to 4:30 p.m.
    Agenda: Presentations and other business of the Council.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, Neurosciences Center Building, 6001 Executive Boulevard, 
Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of 
Extramural Research, Office of the Director, National Institute on 
Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC 
9591, Rockville, MD 20892, 301-443-6487, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: August 11, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-17817 Filed 8-14-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.